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http://dx.doi.org/10.1016/j.jpurol.20Abstract Disorders of sex development (DSD) rarely present prenatally but, as they are very
complex conditions, management should be directed by highly specialised medical teams to
allow consideration of all aspects of diagnosis, treatment and ethical issues. In this brief
review, we present an overview of the prenatal presentation and management of DSD,
including the sonographic appearance of normal genitalia and methods of determining genetic
sex, the prenatal management of pregnancies with the unexpected finding of genital ambiguity
on prenatal ultrasound and a review of the prenatal management of pregnancies at high risk of
DSD. As this is a rapidly developing field, management options will change over time, making
the involvement of clinical geneticists, paediatric endocrinologists and urologists, as well as
fetal medicine specialists, essential in the care of these complex pregnancies. The reader
should also bear in mind that local social, ethical and legal aspects may also influence
management.
ª 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.Introduction
Disorders of sex development (DSD) are very challenging
conditions requiring management by highly specialisedMolecular Genetics Unit, UCL In
c.uk (L.S. Chitty), pierre.chate
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nosis, treatment and ethical issues. Although rare, DSD is
usually identified at the first physical examination after birth.
However, in recent years, DSD has become more and morestitute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.
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Disorders of sexual development 577a prenatal medical issue. Probably the most common
circumstance is a pregnancy presenting with a family history
of an inherited form of DSD. Less common is the discovery of
abnormal genitalia by prenatal ultrasonography or, and very
rarely, discordance between the genetic sex determined
by karyotyping, performed because of an increased risk
of aneuploidy, and the phenotypic sex observed by
ultrasonography. Ideally, these patients should be referred to
a specialised multidisciplinary team including a pediatric
endocrinologist, geneticist, paediatric radiologist and paedi-
atric urological surgeon. This team should also have access to
expertise in hormonal profiling and molecular genetics.
In this paper we shall briefly review some aspects
regarding the prenatal presentation and management of
DSD. We shall start by describing the sonographic appear-
ance of normal genitalia and methods of determining
genetic sex before discussing the prenatal management of
pregnancies with the unexpected finding of genital ambi-
guity on prenatal ultrasound. Finally, we will review the
prenatal management of pregnancies at high risk of DSD,
keeping in mind that this is a rapidly developing field,
dependent not only on the experience of the medical team
but also patient access to advanced technical imaging and
molecular genetic analyses. Local social, ethical and legal
aspects may also influence management.Figure 1 Showing the different angles of the phallus from 12
weeks gestation in a male (upper image) and female (lower
image). Note the size of the phallus is equivalent in both, but it
is the difference in angle that is diagnostic e acute in males
and more obtuse in females.
Figure 2 Doppler ultrasound showing urinary flow from
a proximally placed urinary orifice (D) at the base of the short
phallus (P). (Courtesy F Ushakov, London).Normal appearances and evaluation of fetal
genitalia
The appearance of normal fetal genitalia and the accuracy
of sonographic fetal sex assignment across gestation are well
documented [1,2]. However, reliable identification of fetal
genital dysmorphology requires an experienced operator. In
early pregnancy the genital tubercule is identical in size in
male and female fetuses. From 12 weeks’ gestation the
critical observation is variation in the angle or ‘sagittal sign’
of the tubercle (Fig. 1) which allows for highly accurate
sonographic identification of fetal sex using either 2-D
(>95%) [3] or 3-D [4] ultrasound when performed by a skil-
led sonographer. The downward, or more obtuse angle,
represents a female fetus and the upward, or acute angle,
a male fetus. Sonographic assignment of fetal sex before 12
weeks’ gestation is highly inaccurate [1,2].
Later in pregnancy, assignment is based on direct visu-
alisation of the genital anatomy, including the scrotum and
midline raphe of the penis in males, and the three lines,
representing the labial lines, and uterus in female fetuses.
There are charts of fetal penile length available but their
utility has yet to be proven and different publications give
slightly different normal ranges [5,6]. Three-dimensional
ultrasound is of limited use for sonographic sex determina-
tion in routine practice, but it may be useful in defining
malformations of the external genitalia. Colour flow Doppler
ultrasound is not useful in defining normality, but it can be
helpful in defining the extent of hypospadias if the origin of
micturition can be identified (Fig. 2). Whilst there are
descriptions of normal genital anatomy defined by in-utero
magnetic resonance imaging [7,8], this modality is really of
use in the evaluation of abnormal genitalia when it may add
useful information regarding the genital anatomy, internal
mullerian structures and other anatomical parts [9].Determination of genetic sex
Traditionally, determination of genetic sex has been per-
formed by karyotype, fluorescent in-situ hybridisation
578 L.S. Chitty et al.(FISH) or quantitative fluorescent polymerase chain reac-
tion (qfPCR) analysis of amniocytes or chorionic villi
following invasive techniques such as amniocentesis or
chorionic villus sampling (CVS), both of which carry a risk of
miscarriage of around 0.5e1% in experienced hands [10].
The identification of cell free fetal DNA (cffDNA) circulating
in maternal blood has offered the potential for non-invasive
prenatal testing (NIPT) of fetal genetic material [11]. This
cffDNA is present in maternal blood from 4 weeks’ gesta-
tion, but as the majority of cell free DNA in maternal blood
emanates from the mother herself, there are significant
technical challenges when using cffDNA for genetic diag-
nosis [12]. Cell free fetal DNA represents up to 10% of total
circulating cell free DNA [13,14], increases with gestation
and is very rapidly cleared from plasma at delivery [15]. As
such, this is increasingly being used to identify genes or
alleles in maternal plasma that are not present in the
mother but are in the fetus because they have been
inherited from the father or arisen de novo at conception.
Current applications include fetal sex determination [16],
the diagnosis of single gene disorders such as achondro-
plasia [17] and the determination of fetal Rhesus D status in
RhD negative mothers [18].
NIPT for fetal sex determination relies on detecting
a signal from Y-chromosome sequences in the maternal
plasma. If Y-chromosome sequences are detected, the
fetus is predicted to be a male. If no Y-chromosome
sequences are detected, the fetus is predicted to be
female. This approach can use a variety of Y-chromosome
sequences including SRY, DYS14 and amelogenin [19]. In
the context of DSD it is probably better to use DYS14 than
SRY, since abnormalities in the SRY gene can in itself cause
a DSD. Indeed, in the case of negative detection of these
markers, there is a need to ensure the presence of fetal
DNA (as a control to demonstrate amplification of fetal DNA
sequences). NIPT for fetal sex determination is increas-
ingly used to determine fetal sex in pregnancies at
increased risk of serious X-linked genetic disorders and
congenital adrenal hyperplasia. In the UK and some other
European countries it is now the standard of care in these
situations [20]. It is valued by women and health
professionals alike [21,22] as targeted use of NIPT for sex
determination in these high risk pregnancies is highly
accurate (>99%) when delivered by accredited molecular
genetic laboratories, and can reduce the rate of invasive
testing by around 45%, thereby avoiding uneccesary
exposure to miscarriage risk [23]. In addition, it permits
early cessation of steroid treatment pregnancies at risk of
congenital adrenal hyperplasia (CAH) where the fetus is
predicted to be male [23,24]. Indeed, in some European
centres dexamethasone treatment is delayed until NIPT
performed at 7 weeks’ gestation suggests the presence of
a female fetus, thereby completely avoiding steroid
exposure for all male fetuses. Finally, an economic anal-
ysis, which took account of all aspects of the care pathway,
showed that when used in pregnancies at high risk of
serious X-linked conditions (where parents might elect to
terminate an affected pregnancy) and those at risk of
CAH, NIPT was no more expensive than invasive diagnostic
testing as the savings in invasive tests and uneccesary
steroid treatment more than covered the laboratory costs
of NIPT [25].The management of fetuses presenting with
the unexpected finding of genital ambiguity
Genital abnormalities are a rare finding on prenatal ultra-
sound but can be seen when detailed examination is per-
formed following detection of another structural
abnormality or, and more commonly, when the genitalia are
examined because of parental curiosity. The aetiology of
these unexpected genital anomalies is broad and includes
an isolated anomaly, an underlying genetic syndrome,
intra-uterine fetal growth restriction (IUGFR), chromosomal
abnormalities and, although very rare, anomalies of steroid
biosynthesis or androgen insensitivity, with the most
common association being an error in early fetal develop-
ment which results in bladder or cloacal exstrophy
(Table 1).
The varied aetiology requires a structured approach
to diagnosis and subsequent management, which
should commence with a detailed ultrasound scan and
evaluation of maternal and fetal dopplers. Clitoromegaly
in a female fetus or hypospadias in a male fetus are very
difficult to differentiate sonographically (Fig. 3), although
3-D ultrasound may be useful to distinguish the two
(Fig. 3). Determination of genetic sex is almost always
required in this situation. This can be done by analysis of
cffDNA in maternal blood in most cases but in some
situations full karyotyping following amniocentesis is
required to exclude other chromosomal abnormalities
(Table 1).
Once chromosomal, urinary tract and syndromal aetiol-
ogies are excluded, consideration should be given to steroid
profiling or, in a 46XY fetus, sequencing of the androgen
receptor gene to exclude Androgen Insensitivity Syndromes
(AIS). These investigations are best directed by the DSD
team. Genetic consultation is advisable in most cases
without urinary tract aetiology. A suggested pathway for
investigation is given in Fig. 4.
At present, relevant targeted molecular testing for rare
DSD conditions in the absence of a family history has a low
yield [27]. However, with the development of next gener-
ation sequencing it is likely that it will soon become
possible to test for a wide range of known genetic muta-
tions in cases presenting de novo.
Prenatal management of congenital adrenal
hyperplasia due to 21-hydroxylase deficiency
(CAH)
Amongst the rare adrenal steroidogenesis biosynthesis
disorders that lead to DSD, CAH due to 21-hydroxylase
deficiency (CYP 21 CAH) is less rare than 11-b-hydroxyste-
roids dehydrogenase deficiency. Despite half a century of
experience of CYP 21 CAH, the paediatric management of
this condition remains challenging and the prenatal
management even more so. Neonatal screening for CYP 21
CAH, based on 17-hydroxyprogesterone (17OHP) measure-
ment from blood collected early after birth on filter paper,
identifies affected infants [28e30]. Here, we summarise
the general principles and suggested pathways for the
prenatal diagnosis of CYP 21 CAH and briefly discuss
approaches to prenatal management.
Table 1 Review of all cases with sonographic genital abnormalities seen in a tertiary referral unit over a ten year period with differential diagnosis and suggested
management strategies. This table is adapted from those published in Pajkrt et al., 2008 [26] with additional cases added.
Classification Final diagnosis
(number)
Other sonographic
findings
Karyotype Differential diagnosis Other AIDS to
prenatal diagnosis
Management
Abnormal/ambiguous
Isolated
Hypospadias (1) None 46XY Inadequate production
of testosterone due to
Leydig cell hypoplasia or
biosynthetic defects
e Congenital lipoid
adrenal hyperplasia
e 17a-hydroxylase
deficiency
e 3b-hydroxysteroid
dehydrogenase
deficiency
e 17,20-lyase
deficiency
e 17b-hydroxysteroid
dehydrogenase
deficiency
Partial androgen insen-
sitivity syndrome
5a-reductase defi-
ciency
Ovotesticular DSD
 cffDNA for
genetic sex
 Consider
sequencing of the
Androgen
Receptor gene
Refer to DSD team for
investigation and
counselling
Cliteromegaly (1) None 46XX Congenital adrenal
hyperplasia
e 21-OH deficiency
e 11-OH deficiency
e 3b-hydroxysteroid
dehydrogenase
deficiency
Ovotesticular DSD
Maternally derived
androgens, eg luteoma
of pregnancy
Placental aromatase
deficiency
 cffDNA for
genetic sex
 Amniotic steroid
levels
 Maternal serum
androgen levels
 Maternal urinary
oestrogen levels
 Maternal ovarian
scan for multi-
cystic change
Refer to DSD team for
investigation and
counselling.
Refer to gynaecology/
oncology if luteoma
(continued on next page)
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Table 1 (continued)
Classification Final diagnosis
(number)
Other sonographic
findings
Karyotype Differential diagnosis Other AIDS to
prenatal diagnosis
Management
Luteoma of
pregnancy
(1)
None 46XX
With fetal growth restriction
Hypospadias (4) Abnormal maternal
and fetal dopplers
46XY Aneuploidy
Confined placental
mosaicism
 Fetal biometry
 Invasive testing
to exclude aneu-
ploidy and deter-
mine sex
Serial monitoring in
FMU
Refer to DSD team for
counselling
In combination with urinary tract anomalies
Bladder exstrophy (8) No intra-abdominal
bladder with
micropenis/no penis/
splayed glans. Low
cord insertion
46XY Cloacal exstrophy  cffDNA for
genetic sex
 Detailed anomaly
scan
Refer to combined
fetal-urology team
Cloacal exstrophy (3) Absent intra-
abdominal bladder,
intra-abdominal
cystic mass, dilated
bowel, abnormal
spine.
46XX Aneuploidy
Other cloacal
abnormality
Invasive testing to
exclude aneuploidy
and determine fetal
sex
Refer to combined
fetal-urology team
OEIS (2) Ompalocoele/
gastroschisis,
abnormal spine, no
intra-abdominal
bladder,
hydronephrosis
46XY (1)
46XX (1)
Aneuploidy
Cloacal abnormality
Invasive testing to
exclude aneuploidy
and determine fetal
sex
Refer to combined
fetal-urology team
Unknown (2) Echogenic kidneys 46XY (1)
46XX (1)
Invasive testing to
exclude aneuploidy
and determine fetal
sex
Refer to combined
fetal-urology/
nephrology team and
clinical geneticist
With other anomalies
Mosaic ring
chromosome 8
Complex cardiac
anomaly, cerebral
ventriculomegaly,
urachal cyst
46XY mos ring 8 Aneuploidy
Bardet Biedel
Smith Lemli Opitz
syndrome
Opitz Syndrome
Opitz-G or BBB syndrome
VATER association
CHARGE association
Other genetic syndromes
 Invasive testing
to exclude aneu-
ploidy and deter-
mine genetic sex
 cffDNA for fetal
sex only if inva-
sive testing
declined
 Detailed scan
 Autosomal reces-
sive condition so
take family
history for other
affected
members and
consanguinity.
Bardet Biedel (1) Echogeneic kidneys,
polydactyly
46XY
Malpeuch syndrome
(1)
Cleft lip and palate,
IUGR
46XY
Cranio-cerebellar- Posterior fossa cyst 46XY
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 Maternal urinary
steroids to
exclude SLO
 Clinical genetics
referral
 Refer all relevant
paediatric
specialists for
discussion of
prognosis
cardiac syndrome (1) with hypoplastic
cerebellar vermis,
complex cardiac
anomaly, talipes
SLO (2) Polydactyly, IUFGR,
oedema, cleft lip,
CNS anomalies.
46XY (2)
Phenotype discordant with genotype
Isolated
Androgen insensitivity
syndrome
None 46XY Invasive testing and/
or cffDNA to confirm
discordance between
genotype and
phenotype. Nb. In
situations where
there is an
abnormality in the
SRY gene cffDNA using
SRY may give
misleading results
Refer specialist DSD
team
Laboratory/clerical
error (2)
None 46XY (2) cffDNA to confirm
fetal genetic sex
With other sonographic abnormalities
Campomelic dysplasia
(2)
Bowing of femora
þ/ tibia and fibula.
Micrognathia, cardiac
anomalies
46XY (2) cffDNA to confirm
fetal genetic sex
Refer clinical
geneticist/skeletal
dysplasia clinic
SLO (2) Polydactyly, IUFR,
oedema, cleft lip,
CNS anomalies.
46XY (2)
cffDNA e cell free fetal DNA; DSD e disorders of sex developments; FMU e fetal medicine unit; IUFGR e intra-uterine fetal growth restriction; SLO e Smith Lemli Optitz.
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Figure 3 Ultrasound and postnatal images of cliteromegaly (A, B) and hypospadias (C, D) using 2-D ultrasound. A 3-D image taken
at 30 weeks gestation and postnatal view is also shown (E, F) (Courtesy T.E. Cohen-Overbeek and I.A.L. Groenenberg, Department
of Obstetrics and Gynaecology, Erasmus MC, Rotterdam).
582 L.S. Chitty et al.Definitive prenatal diagnosis of CYP 21 CAH is limited to
families where there is a previously affected child (index
case). It requires molecular genetic analysis of both the
index case and parents, parental DNA being essential to
determine segregation of alleles of the CYP21 gene. Fami-
lies with affected individuals should be offered genetic
counselling, which should be delivered by suitably trained
individuals in specialist centres. Molecular genetic analysis
is complex [31,32] although less than 12 mutations account
for 90e95% of the mutant alleles. The phenotype is not
universally correlated to the genotype [32]. Ideally, the
prenatal diagnostic pathway should commence with pre-
pregnancy parental counselling by an expert team.Figure 4 Suggested management algorithm for unexpected pr
(Adapted from Pajkrt and Chitty 2008 [26]).Parents need to understand that this is an autosomal
recessive condition with the consequent 1:4 risk of an
affected child in every pregnancy. They need to understand
that all affected offspring will require supplementation,
but that only affected females are at risk of genital virili-
sation. Thus the risk of requiring postnatal surgical inter-
vention is only 1:8 overall. Finally, and depending upon the
severity, availability of definitive diagnosis, local social
policy and parental attitudes, the possibility of pregnancy
termination should be discussed. It is worth noting that
parental attitudes may sometimes change with time,
making it important to reassess the situation in every new
pregnancy. In view of the availability of prenatal diagnosisesentation of genital abnormalities on prenatal ultrasound.
Disorders of sexual development 583and treatment, experts managing these families should
strive to emphasise the need for early referral in preg-
nancy, an ideal difficult to achieve.
When a family request prenatal diagnosis for CYP 21
CAH, the first step is to confirm the pregnancy and perform
an ultrasound scan for accurate dating and exclusion of
multiple fetuses or an empty gestational sac [23]. Genetic
fetal sex determination can be performed reliably using
NIPT and analysis of cffDNA obtained from maternal plasma
from 7 weeks’ gestation. Definitive molecular genetic
diagnosis of CYP21 still requires analysis of chorionic villi
following CVS from 11 weeks’ gestation. Readers should be
aware that the progress in NIPT is rapid and technological
advances have recently allowed definitive diagnosis of
other autosomal recessive and X-linked conditions [33,34]
and so definitive molecular diagnosis of CYP21 using NIPT
may not be that far distant.
In rare cases, the unexpected identification of a fetus
with abnormal external genitalia at the time of a routine
ultrasound scan, subsequently found to have a 46XX
karyotype, may lead to analysis of the CYP 21 gene both in
the fetus, using cultured amniocytes, chorionic villi or
(rarely) fetal blood, and parental DNA for definitive
molecular diagnosis (Table 1). Realistically this situation
only arises at or after 20 weeks’ gestation when routine
anomaly scanning is performed. As this is beyond the
potential prenatal treatment window (see below), parents
should be carefully counselled regarding the risks and
benefits of invasive prenatal diagnosis versus the risk of
miscarriage versus diagnosis at birth.Issues arising in CYP 21 CAH prenatal
treatment
Prenatal treatment aimed at preventing masculinisation of
affected female fetuses may be effective for fetuses at risk
for classic CYP 21 CAH but is not appropriate for non-classic
types (13e16). Although today’s early diagnosis of fetal sex
allows restriction of steroid treatment to mothers carrying
female fetuses, as summarised in the consensus statement
on CAH management, “the appropriateness, ethics, and
outcomes of the prenatal treatment of CAH with dexa-
methasone remain controversial” [28]. The report
concludes that provided treatment with maternal dexa-
methasone is commenced early in pregnancy (prior to 9
weeks after the last menstrual period) genital virilisation in
affected female fetuses is ameliorated, an effect that by
itself is considered as positive [35e38]. However, the
statement that, “it completely eliminates virilisation in
more than 85%,” should be viewed with caution as there has
been no systematic evaluation of patients undergoing
prenatal treatment by urethroscopy performed by a pedi-
atric urological surgeon and the level of confluency
between the vagina and the urethra is not known
[30,31,38]. Furthermore, significant variations in outcome
have been observed. These can have several aetiological
factors including late onset of prenatal treatment, unreli-
able dating of the pregnancy, inappropriate dexametha-
sone administration (either dose and/or frequency of
administration), poor maternal compliance and possible
differences in androgen sensitivity.Although no clinically significant adverse effects of
long-term prenatal exposure to dexamethasone has been
reported, data on long-term follow-up is limited [37,39,40]
and questions have been raised as to the possible adverse
effects on cognitive function in a small series [39e41]. In
terms of maternal side-effects, treated mothers experience
greater weight gain, oedema, and striae than untreated
mothers but no evidence of an increased incidence of either
hypertension or gestational diabetes has been observed
[36,38,40]. Further concerns have been raised recently,
following reports in both humans and animals, regarding the
potential effects of prenatal dexamethasone exposure on
gene expression during the early and critical developmental
period. These observations have raised further questions as
to the safety of such treatment [39e44]. Taking all these
factors into consideration, there is a widely held view that
prenatal dexamethasone treatment of a mother carrying
a female fetus at risk of CYP 21 CAH should only be per-
formed by a multidisciplinary experienced team in the
context of a clinical trial with commitment to long-term
follow-up of both mother and child.
Conclusions
Prenatal presentation of DSD is rare but demands sensitive
and timelymanagement by an experienced and expert team,
which should include expertise in fetal medicine, genetics,
paediatric endocrinology and paediatric urology. Rapid
developments in molecular genetics and other technology
will influence diagnosis andmanagement, possibly rendering
some of the conclusions of this paper outdated. Existing and
any future prenatal treatment requires co-ordinated and
long-term follow-up studies to determine the true benefits
and costs. Since these conditions are rare, this will require
multicentre, probably international, studies.
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